Nanologica AB (ST:NICA) — Market Cap & Net Worth
Market Cap & Net Worth: Nanologica AB (NICA)
Nanologica AB (ST:NICA) has a market capitalization of $11.29 Million (Skr104.88 Million) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #26841 globally and #570 in its home market, demonstrating a -7.80% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nanologica AB's stock price Skr0.32 by its total outstanding shares 328769842 (328.77 Million). Also see Nanologica AB total assets for a full breakdown of the balance sheet.
Nanologica AB Market Cap History: 2017 to 2026
Nanologica AB's market capitalization history from 2017 to 2026. Data shows change from $304.97 Million to $11.29 Million (-33.39% CAGR). Also see cash efficiency ratio of Nanologica AB for how efficiently the company converts equity into cash flow.
Nanologica AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nanologica AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check NICA stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.31x
Nanologica AB's market cap is 1.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $304.97 Million | $2.60 Million | -$20.10 Million | 117.30x | N/A |
| 2018 | $112.37 Million | $4.15 Million | -$20.89 Million | 27.11x | N/A |
| 2019 | $371.04 Million | $10.23 Million | -$21.47 Million | 36.28x | N/A |
| 2020 | $474.10 Million | $16.14 Million | -$24.83 Million | 29.38x | N/A |
| 2021 | $484.72 Million | $12.91 Million | -$50.13 Million | 37.53x | N/A |
| 2022 | $353.81 Million | $1.55 Million | -$55.09 Million | 227.53x | N/A |
| 2023 | $367.96 Million | $1.44 Million | -$75.16 Million | 255.00x | N/A |
| 2024 | $64.39 Million | $14.54 Million | -$65.63 Million | 4.43x | N/A |
| 2025 | $27.60 Million | $21.13 Million | -$51.29 Million | 1.31x | N/A |
Competitor Companies of NICA by Market Capitalization
Companies near Nanologica AB in the global market cap rankings as of September 19, 2026. Review tangible net worth ratio of Nanologica AB to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Nanologica AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Nanologica AB Historical Marketcap From 2017 to 2026
Between 2017 and today, Nanologica AB's market cap moved from $304.97 Million to $ 11.29 Million, with a yearly change of -33.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr11.29 Million | -59.10% |
| 2025 | Skr27.60 Million | -57.14% |
| 2024 | Skr64.39 Million | -82.50% |
| 2023 | Skr367.96 Million | +4.00% |
| 2022 | Skr353.81 Million | -27.01% |
| 2021 | Skr484.72 Million | +2.24% |
| 2020 | Skr474.10 Million | +27.78% |
| 2019 | Skr371.04 Million | +230.19% |
| 2018 | Skr112.37 Million | -63.15% |
| 2017 | Skr304.97 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Nanologica AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.29 Million USD |
| MoneyControl | $11.29 Million USD |
| MarketWatch | $11.29 Million USD |
| marketcap.company | $11.29 Million USD |
| Reuters | $11.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nanologica AB
Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange prod… Read more